Apoptosis and non-apoptotic deaths in cancer development and treatment response

Cancer Treatment Reviews

Volumn 34, Issue 8, 2008, Pages 737-749

  de Bruin, Elza C ^a   Medema, Jan Paul ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Apoptosis; Autophagy; Mitotic catastrophe; Necrosis; Radiotherapy; Treatment response; Tumorigenesis

Indexed keywords

ANTINEOPLASTIC AGENT; CELECOXIB; FLUOROURACIL; PROTEIN P53; RECOMBINANT SOLUBLE TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SURVIVIN; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

APOPTOSIS; AUTOPHAGY; CANCER CELL; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CELL DEATH; CLINICAL TRIAL; COLORECTAL CANCER; HUMAN; MITOSIS; MOLECULAR MECHANICS; NONHUMAN; OUTCOME ASSESSMENT; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TARGET CELL; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS INDUCING FACTOR; AUTOPHAGY; CELL DEATH; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; DRUG DELIVERY SYSTEMS; HUMANS; NECROSIS; NEOPLASMS; PHARMACOGENETICS; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS;

EID: 56249102048     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2008.07.001     Document Type: Review

References (164)

1. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
2. Johnstone R.W., Ruefli A.A., and Lowe S.W. Apoptosis: a link between cancer genetics and chemotherapy. Cell 108 (2002) 153-164
3. Brown J.M., and Attardi L.D. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 5 (2005) 231-237
4. Kerr J.F., Wyllie A.H., and Currie A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26 (1972) 239-257
5. Fadok V.A., Bratton D.L., Rose D.M., Pearson A., Ezekewitz R.A., and Henson P.M. A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature 405 (2000) 85-90
6. Wei M.C., Zong W.X., Cheng E.H., et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292 (2001) 727-730
7. Kuwana T., Mackey M.R., Perkins G., et al. Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell 111 (2002) 331-342
8. Letai A., Bassik M.C., Walensky L.D., Sorcinelli M.D., Weiler S., and Korsmeyer S.J. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2 (2002) 183-192
9. Kuwana T., Bouchier-Hayes L., Chipuk J.E., et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 17 (2005) 525-535
10. Certo M., Del G.M., Nishino M., et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic Bcl-2 family members. Cancer Cell 9 (2006) 351-365
11. Chen L., Willis S.N., Wei A., et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17 (2005) 393-403
12. Stennicke H.R., Deveraux Q.L., Humke E.W., Reed J.C., Dixit V.M., and Salvesen G.S. Caspase-9 can be activated without proteolytic processing. J Biol Chem 274 (1999) 8359-8362
13. Boatright K.M., Renatus M., Scott F.L., et al. A unified model for apical caspase activation. Mol Cell 11 (2003) 529-541
14. Pop C., Timmer J., Sperandio S., and Salvesen G.S. The apoptosome activates caspase-9 by dimerization. Mol Cell 22 (2006) 269-275
15. Kischkel F.C., Hellbardt S., Behrmann I., et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 14 (1995) 5579-5588
16. Nagata S. Apoptosis by death factor. Cell 88 (1997) 355-365
17. Donepudi M., Mac S.A., Briand C., and Grutter M.G. Insights into the regulatory mechanism for caspase-8 activation. Mol Cell 11 (2003) 543-549
18. Bao Q., and Shi Y. Apoptosome: a platform for the activation of initiator caspases. Cell Death Differ 14 (2007) 56-65
19. Irmler M., Thome M., Hahne M., et al. Inhibition of death receptor signals by cellular FLIP. Nature 388 (1997) 190-195
20. Burns T.F., and El Deiry W.S. Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach. J Biol Chem 276 (2001) 37879-37886
21. Peter M.E. The flip side of FLIP. Biochem J 382 (2004) e1-e3
22. Hyer M.L., Samuel T., and Reed J.C. The FLIP-side of Fas signaling. Clin Cancer Res 12 (2006) 5929-5931
23. Chang D.W., Xing Z., Pan Y., et al. c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J 21 (2002) 3704-3714
24. Micheau O., Thome M., Schneider P., et al. The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J Biol Chem 277 (2002) 45162-45171
25. Sharp D.A., Lawrence D.A., and Ashkenazi A. Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis. J Biol Chem 280 (2005) 19401-19409
26. Wilson T.R., McLaughlin K.M., McEwan M., et al. c-FLIP: a key regulator of colorectal cancer cell death. Cancer Res 67 (2007) 5754-5762
27. Li H., Zhu H., Xu C.J., and Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94 (1998) 491-501
28. Roy N., Deveraux Q.L., Takahashi R., Salvesen G.S., and Reed J.C. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J 16 (1997) 6914-6925
29. Eckelman B.P., and Salvesen G.S. The human anti-apoptotic proteins cIAP1 and cIAP2 bind but do not inhibit caspases. J Biol Chem 281 (2006) 3254-3260
30. Du C., Fang M., Li Y., Li L., and Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102 (2000) 33-42
31. Verhagen A.M., Ekert P.G., Pakusch M., et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102 (2000) 43-53
32. Suzuki Y., Imai Y., Nakayama H., Takahashi K., Takio K., and Takahashi R. A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol Cell 8 (2001) 613-621
33. Vousden K.H., and Lane D.P. p53 in health and disease. Nat Rev Mol Cell Biol 8 (2007) 275-283
34. Donehower L.A., Harvey M., Slagle B.L., et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356 (1992) 215-221
35. Harvey M., McArthur M.J., Montgomery Jr. C.A., Butel J.S., Bradley A., and Donehower L.A. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat Genet 5 (1993) 225-229
36. Schmitt C.A., McCurrach M.E., de Stanchina E., Wallace-Brodeur R.R., and Lowe S.W. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 13 (1999) 2670-2677
37. Rampino N., Yamamoto H., Ionov Y., et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275 (1997) 967-969
38. Kondo S., Shinomura Y., Miyazaki Y., et al. Mutations of the bak gene in human gastric and colorectal cancers. Cancer Res 60 (2000) 4328-4330
39. Tsujimoto Y., Finger L.R., Yunis J., Nowell P.C., and Croce C.M. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 226 (1984) 1097-1099
40. McDonnell T.J., Deane N., Platt F.M., et al. Bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 57 (1989) 79-88
41. Moller P., Koretz K., Leithauser F., et al. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int J Cancer 57 (1994) 371-377
42. Medema J.P., de Jong J., van Hall T., Melief C.J., and Offringa R. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J Exp Med 190 (1999) 1033-1038
43. Zhou X.D., Yu J.P., Chen H.X., Yu H.G., and Luo H.S. Expression of cellular FLICE-inhibitory protein and its association with p53 mutation in colon cancer. World J Gastroenterol 11 (2005) 2482-2485
44. Klionsky D.J., and Emr S.D. Autophagy as a regulated pathway of cellular degradation. Science 290 (2000) 1717-1721
45. Baehrecke E.H. Autophagic programmed cell death in Drosophila. Cell Death Differ 10 (2003) 940-945
46. Mizushima N., Noda T., Yoshimori T., et al. A protein conjugation system essential for autophagy. Nature 395 (1998) 395-398
47. Mizushima N., Sugita H., Yoshimori T., and Ohsumi Y. A new protein conjugation system in human. The counterpart of the yeast Apg12p conjugation system essential for autophagy. J Biol Chem 273 (1998) 33889-33892
48. Mizushima N., Yamamoto A., Hatano M., et al. Dissection of autophagosome formation using Apg5-deficient mouse embryonic stem cells. J Cell Biol 152 (2001) 657-668
49. Matsushita M., Suzuki N.N., Obara K., Fujioka Y., Ohsumi Y., and Inagaki F. Structure of Atg5.Atg16, a complex essential for autophagy. J Biol Chem 282 (2007) 6763-6772
50. Wang C.W., and Klionsky D.J. The molecular mechanism of autophagy. Mol Med 9 (2003) 65-76
51. Petiot A., Ogier-Denis E., Blommaart E.F., Meijer A.J., and Codogno P. Distinct classes of phosphatidylinositol 3′-kinases are involved in signaling pathways that control macroautophagy in HT-29 cells. J Biol Chem 275 (2000) 992-998
52. Arico S., Petiot A., Bauvy C., et al. The tumor suppressor PTEN positively regulates macroautophagy by inhibiting the phosphatidylinositol 3-kinase/protein kinase B pathway. J Biol Chem 276 (2001) 35243-35246
53. Furuya N., Yu J., Byfield M., Pattingre S., and Levine B. The evolutionarily conserved domain of Beclin1 is required for Vps34 binding, autophagy and tumor suppressor function. Autophagy 1 (2005) 46-52
54. Alva A.S., Gultekin S.H., and Baehrecke E.H. Autophagy in human tumors: cell survival or death?. Cell Death Differ 11 (2004) 1046-1048
55. Liang X.H., Jackson S., Seaman M., et al. Induction of autophagy and inhibition of tumorigenesis by Beclin1. Nature 402 (1999) 672-676
56. Yue Z., Jin S., Yang C., Levine A.J., and Heintz N. Beclin1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci USA 100 (2003) 15077-15082
57. Marino G., Salvador-Montoliu N., Fueyo A., Knecht E., Mizushima N., and Lopez-Otin C. Tissue-specific autophagy alterations and increased tumorigenesis in mice deficient in ATG4C/autophagin-3. J Biol Chem (2007)
58. Crighton D., Wilkinson S., O'Prey J., et al. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 126 (2006) 121-134
59. Furuta S., Hidaka E., Ogata A., Yokota S., and Kamata T. Ras is involved in the negative control of autophagy through the class I PI3-kinase. Oncogene 23 (2004) 3898-3904
60. Shaw R.J., and Cantley L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441 (2006) 424-430
61. Edinger A.L., and Thompson C.B. Defective autophagy leads to cancer. Cancer Cell 4 (2003) 422-424
62. Jin S., and White E. Role of autophagy in cancer: management of metabolic stress. Autophagy 3 (2007) 28-31
63. Mathew R., Kongara S., Beaudoin B., et al. Autophagy suppresses tumor progression by limiting chromosomal instability. Genes Dev 21 (2007) 1367-1381
64. Ahn C.H., Jeong E.G., Lee J.W., et al. Expression of Beclin-1, an autophagy-related protein, in gastric and colorectal cancers. APMIS 115 (2007) 1344-1349
65. Lum J.J., Bauer D.E., Kong M., et al. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 120 (2005) 237-248
66. Amaravadi R.K., Yu D., Lum J.J., et al. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 117 (2007) 326-336
67. Klionsky D.J., Abeliovich H., Agostinis P., et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 4 (2008) 151-175
68. Molz L., Booher R., Young P., and Beach D. CDC2 and the regulation of mitosis: six interacting mcs genes. Genetics 122 (1989) 773-782
69. Roninson I.B., Broude E.V., and Chang B.D. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat 4 (2001) 303-313
70. Castedo M., Perfettini J.L., Roumier T., Andreau K., Medema R., and Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 23 (2004) 2825-2837
71. Eom Y.W., Kim M.A., Park S.S., et al. Two distinct modes of cell death induced by doxorubicin: apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype. Oncogene 24 (2005) 4765-4777
72. Chen T., Hevi S., Gay F., et al. Complete inactivation of DNMT1 leads to mitotic catastrophe in human cancer cells. Nat Genet 39 (2007) 391-396
73. Reinhardt H.C., Aslanian A.S., Lees J.A., and Yaffe M.B. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 11 (2007) 175-189
74. Strauss S.J., Higginbottom K., Juliger S., et al. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines. Cancer Res 67 (2007) 2783-2790
75. Jin P., Hardy S., and Morgan D.O. Nuclear localization of cyclin B1 controls mitotic entry after DNA damage. J Cell Biol 141 (1998) 875-885
76. Chan T.A., Hermeking H., Lengauer C., Kinzler K.W., and Vogelstein B. 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 401 (1999) 616-620
77. Brown E.J., and Baltimore D. ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev 14 (2000) 397-402
78. Takai H., Tominaga K., Motoyama N., et al. Aberrant cell cycle checkpoint function and early embryonic death in Chk1(-/-) mice. Genes Dev 14 (2000) 1439-1447
79. Niida H., Tsuge S., Katsuno Y., Konishi A., Takeda N., and Nakanishi M. Depletion of Chk1 leads to premature activation of Cdc2-cyclin B and mitotic catastrophe. J Biol Chem 280 (2005) 39246-39252
80. Bunz F., Dutriaux A., Lengauer C., et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282 (1998) 1497-1501
81. Lens S.M., Wolthuis R.M., Klompmaker R., et al. Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. EMBO J 22 (2003) 2934-2947
82. Bharadwaj R., and Yu H. The spindle checkpoint, aneuploidy, and cancer. Oncogene 23 (2004) 2016-2027
83. Carmena M., and Earnshaw W.C. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 4 (2003) 842-854
84. Lens S.M., Vader G., and Medema R.H. The case for Survivin as mitotic regulator. Curr Opin Cell Biol 18 (2006) 616-622
85. Okada H., and Mak T.W. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 4 (2004) 592-603
86. Chen J.G., and Horwitz S.B. Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs. Cancer Res 62 (2002) 1935-1938
87. Vogel C., Hager C., and Bastians H. Mechanisms of mitotic cell death induced by chemotherapy-mediated G2 checkpoint abrogation. Cancer Res 67 (2007) 339-345
88. Tu S.P., Cui J.T., Liston P., et al. Gene therapy for colon cancer by adeno-associated viral vector-mediated transfer of Survivin Cys84Ala mutant. Gastroenterology 128 (2005) 361-375
89. Duffy M.J., O'Donovan N., Brennan D.J., Gallagher W.M., and Ryan B.M. Survivin: a promising tumor biomarker. Cancer Lett 249 (2007) 49-60
90. Kawasaki H., Toyoda M., Shinohara H., et al. Expression of Survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer 91 (2001) 2026-2032
91. Ambrosini G., Adida C., and Altieri D.C. A novel anti-apoptosis gene, Survivin, expressed in cancer and lymphoma. Nat Med 3 (1997) 917-921
92. Verdecia M.A., Huang H., Dutil E., Kaiser D.A., Hunter T., and Noel J.P. Structure of the human anti-apoptotic protein Survivin reveals a dimeric arrangement. Nat Struct Biol 7 (2000) 602-608
93. Kawasaki H., Altieri D.C., Lu C.D., Toyoda M., Tenjo T., and Tanigawa N. Inhibition of apoptosis by Survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58 (1998) 5071-5074
94. Rodel F., Hoffmann J., Grabenbauer G.G., et al. High Survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection. Strahlenther Onkol 178 (2002) 426-435
95. Rodel F., Hoffmann J., Distel L., et al. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 65 (2005) 4881-4887
96. Vercammen D., Beyaert R., Denecker G., et al. Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor. J Exp Med 187 (1998) 1477-1485
97. Vercammen D., Brouckaert G., Denecker G., et al. Dual signaling of the Fas receptor: initiation of both apoptotic and necrotic cell death pathways. J Exp Med 188 (1998) 919-930
98. Holler N., Zaru R., Micheau O., et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol 1 (2000) 489-495
99. Festjens N., Vanden Berghe T., Cornelis S., and Vandenabeele P. RIP1, a kinase on the crossroads of a cell's decision to live or die. Cell Death Differ 14 (2007) 400-410
100. Lin Y., Choksi S., Shen H.M., et al. Tumor necrosis factor-induced nonapoptotic cell death requires receptor-interacting protein-mediated cellular reactive oxygen species accumulation. J Biol Chem 279 (2004) 10822-10828
101. Lopez-Sanchez N., Rodriguez J.R., and Frade J.M. Mitochondrial c-Jun NH2-terminal kinase prevents the accumulation of reactive oxygen species and reduces necrotic damage in neural tumor cells that lack trophic support. Mol Cancer Res 5 (2007) 47-60
102. Kim C.H., Han S.I., Lee S.Y., et al. Protein kinase C-ERK1/2 signal pathway switches glucose depletion-induced necrosis to apoptosis by regulating superoxide dismutases and suppressing reactive oxygen species production in A549 lung cancer cells. J Cell Physiol 211 (2007) 371-385
103. Ha H.C., and Snyder S.H. Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. Proc Natl Acad Sci USA 96 (1999) 13978-13982
104. Cipriani G., Rapizzi E., Vannacci A., Rizzuto R., Moroni F., and Chiarugi A. Nuclear poly(ADP-ribose) polymerase-1 rapidly triggers mitochondrial dysfunction. J Biol Chem 280 (2005) 17227-17234
105. Yu S.W., Wang H., Poitras M.F., et al. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 297 (2002) 259-263
106. Xu Y., Huang S., Liu Z.G., and Han J. Poly(ADP-ribose) polymerase-1 signaling to mitochondria in necrotic cell death requires RIP1/TRAF2-mediated JNK1 activation. J Biol Chem 281 (2006) 8788-8795
107. Zhang S., Lin Y., Kim Y.S., Hande M.P., Liu Z.G., and Shen H.M. c-Jun N-terminal kinase mediates hydrogen peroxide-induced cell death via sustained poly(ADP-ribose) polymerase-1 activation. Cell Death Differ 14 (2007) 1001-1010
108. Leist M., and Jaattela M. Four deaths and a funeral: from caspases to alternative mechanisms. Nat Rev Mol Cell Biol 2 (2001) 589-598
109. Aggarwal B.B., Shishodia S., Sandur S.K., Pandey M.K., and Sethi G. Inflammation and cancer: how hot is the link?. Biochem Pharmacol 72 (2006) 1605-1621
110. Knight B., Yeoh G.C., Husk K.L., et al. Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice. J Exp Med 192 (2000) 1809-1818
111. Arnott C.H., Scott K.A., Moore R.J., Robinson S.C., Thompson R.G., and Balkwill F.R. Expression of both TNFα receptor subtypes is essential for optimal skin tumour development. Oncogene 23 (2004) 1902-1910
112. Vagefi P.A., and Longo W.E. Colorectal cancer in patients with inflammatory bowel disease. Clin Colorectal Cancer 4 (2005) 313-319
113. Steinbach G., Lynch P.M., Phillips R.K., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342 (2000) 1946-1952
114. Bertagnolli M.M. Chemoprevention of colorectal cancer with cyclooxygenase-2 inhibitors: two steps forward, one step back. Lancet Oncol 8 (2007) 439-443
115. Brown J.M., and Wilson G. Apoptosis genes and resistance to cancer therapy: what does the experimental and clinical data tell us?. Cancer Biol Ther 2 (2003) 477-490
116. Sugao Y., Koji T., Yao T., Ueki T., and Tsuneyoshi M. The incidence of apoptosis during colorectal tumorigenesis. Int J Surg Pathol 8 (2000) 123-132
117. Schwandner O., Schiedeck T.H., Bruch H.P., Duchrow M., Windhoevel U., and Broll R. Apoptosis in rectal cancer: prognostic significance in comparison with clinical histopathologic, and immunohistochemical variables. Dis Colon Rectum 43 (2000) 1227-1236
118. Hilska M., Collan Y.U., VJ O.L., et al. The significance of tumor markers for proliferation and apoptosis in predicting survival in colorectal cancer. Dis Colon Rectum 48 (2005) 2197-2208
119. Adell G.C., Zhang H., Evertsson S., Sun X.F., Stal O.H., and Nordenskjold B.A. Apoptosis in rectal carcinoma: prognosis and recurrence after preoperative radiotherapy. Cancer 91 (2001) 1870-1875
120. de Bruin E.C., van de Velde C.J., van de P.S., et al. Prognostic value of apoptosis in rectal cancer patients of the dutch total mesorectal excision trial: radiotherapy is redundant in intrinsically high-apoptotic tumors. Clin Cancer Res 12 (2006) 6432-6436
121. Rodel C., Grabenbauer G.G., Papadopoulos T., et al. Apoptosis as a cellular predictor for histopathologic response to neoadjuvant radiochemotherapy in patients with rectal cancer. Int J Radiat Oncol Biol Phys 52 (2002) 294-303
122. Tannapfel A., Nusslein S., Fietkau R., Katalinic A., Kockerling F., and Wittekind C. Apoptosis, proliferation, Bax, Bcl-2 and p53 status prior to and after preoperative radiochemotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 41 (1998) 585-591
123. Langlois N.E., Lamb J., Eremin O., and Heys S.D. Apoptosis in colorectal carcinoma occurring in patients aged 45 years and under: relationship to prognosis, mitosis, and immunohistochemical demonstration of p53, c-myc and Bcl-2 protein products. J Pathol 182 (1997) 392-397
124. Sinicrope F.A., Hart J., Hsu H.A., Lemoine M., Michelassi F., and Stephens L.C. Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinomas. Clin Cancer Res 5 (1999) 1793-1804
125. Michael-Robinson J.M., Biemer-Huttmann A., Purdie D.M., et al. Tumour infiltrating lymphocytes and apoptosis are independent features in colorectal cancer stratified according to microsatellite instability status. Gut 48 (2001) 360-366
126. Elkablawy M.A., Maxwell P., Williamson K., Anderson N., and Hamilton P.W. Apoptosis and cell-cycle regulatory proteins in colorectal carcinoma: relationship to tumour stage and patient survival. J Pathol 194 (2001) 436-443
127. Noguchi T., Kikuchi R., Ono K., Takeno S., Moriyama H., and Uchida Y. Prognostic significance of p27/kip1 and apoptosis in patients with colorectal carcinoma. Oncol Rep 10 (2003) 827-831
128. Rupa J.D., de Bruine A.P., Gerbers A.J., et al. Simultaneous detection of apoptosis and proliferation in colorectal carcinoma by multiparameter flow cytometry allows separation of high and low-turnover tumors with distinct clinical outcome. Cancer 97 (2003) 2404-2411
129. Bendardaf R., Ristamaki R., Kujari H., et al. Apoptotic index and Bcl-2 expression as prognostic factors in colorectal carcinoma. Oncology 64 (2003) 435-442
130. Smith F.M., Reynolds J.V., Miller N., Stephens R.B., and Kennedy M.J. Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy. Eur J Surg Oncol 32 (2006) 55-64
131. de Heer P., Gosens M.J., de Bruin E.C., et al. Cyclooxygenase 2 expression in rectal cancer is of prognostic significance in patients receiving preoperative radiotherapy. Clin Cancer Res 13 (2007) 2955-2960
132. Schmitt C.A., Rosenthal C.T., and Lowe S.W. Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med 6 (2000) 1029-1035
133. Kawai K., Watabe S., Matsuda M., Sakamoto K., and Kamano T. Correlation between expression of orotate phosphoribosyl transferase and 5-fluorouracil sensitivity, as measured by apoptosis index in colorectal cancer tissue. Int J Gastrointest Cancer 35 (2005) 197-203
134. Gudkov A.V., and Komarova E.A. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer 3 (2003) 117-129
135. Ruth A.C., and Roninson I.B. Effects of the multidrug transporter P-glycoprotein on cellular responses to ionizing radiation. Cancer Res 60 (2000) 2576-2578
136. Abend M. Reasons to reconsider the significance of apoptosis for cancer therapy. Int J Radiat Biol 79 (2003) 927-941
137. Paglin S., Hollister T., Delohery T., et al. A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res 61 (2001) 439-444
138. Kanzawa T., Kondo Y., Ito H., Kondo S., and Germano I. Induction of autophagic cell death in malignant glioma cells by arsenic trioxide. Cancer Res 63 (2003) 2103-2108
139. Kondo Y., Kanzawa T., Sawaya R., and Kondo S. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 5 (2005) 726-734
140. Ito H., Daido S., Kanzawa T., Kondo S., and Kondo Y. Radiation-induced autophagy is associated with LC3 and its inhibition sensitizes malignant glioma cells. Int J Oncol 26 (2005) 1401-1410
141. Ravikumar B., Berger Z., Vacher C., O'Kane C.J., and Rubinsztein D.C. Rapamycin pre-treatment protects against apoptosis. Hum Mol Genet 15 (2006) 1209-1216
142. Abedin M.J., Wang D., McDonnell M.A., Lehmann U., and Kelekar A. Autophagy delays apoptotic death in breast cancer cells following DNA damage. Cell Death Differ 14 (2007) 500-510
143. Cao C., Subhawong T., Albert J.M., et al. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res 66 (2006) 10040-10047
144. Kim K.W., Mutter R.W., Cao C., et al. Autophagy for cancer therapy through inhibition of pro-apoptotic proteins and mammalian target of rapamycin signaling. J Biol Chem 281 (2006) 36883-36890
145. Moretti L., Attia A., Kim K.W., and Lu B. Crosstalk between Bak/Bax and mTOR signaling regulates radiation-induced autophagy. Autophagy 3 (2007) 142-144
146. Atkins M.B., Hidalgo M., Stadler W.M., et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22 (2004) 909-918
147. Chollet P., Abrial C., Tacca O., et al. Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer. Clin Breast Cancer 7 (2006) 336-338
148. Cho D., Signoretti S., Regan M., Mier J.W., and Atkins M.B. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res 13 (2007) 758s-763s
149. Weichert W., Kristiansen G., Schmidt M., et al. Polo-like kinase 1 expression is a prognostic factor in human colon cancer. World J Gastroenterol 11 (2005) 5644-5650
150. Takemasa I., Yamamoto H., Sekimoto M., et al. Overexpression of CDC25B phosphatase as a novel marker of poor prognosis of human colorectal carcinoma. Cancer Res 60 (2000) 3043-3050
151. Smits V.A., Klompmaker R., Arnaud L., Rijksen G., Nigg E.A., and Medema R.H. Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat Cell Biol 2 (2000) 672-676
152. Sarela A.I., Macadam R.C., Farmery S.M., Markham A.F., and Guillou P.J. Expression of the antiapoptosis gene, Survivin, predicts death from recurrent colorectal carcinoma. Gut 46 (2000) 645-650
153. Romagnoli M., Trichet V., David C., et al. Significant impact of Survivin on myeloma cell growth. Leukemia 21 (2007) 1070-1078
154. Cahill D.P., Lengauer C., Yu J., et al. Mutations of mitotic checkpoint genes in human cancers. Nature 392 (1998) 300-303
155. Stewart Z.A., Westfall M.D., and Pietenpol J.A. Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol Sci 24 (2003) 139-145
156. Cohen-Jonathan E., Bernhard E., and McKenna W.G. How does radiation kill cells?. Curr Opin Chem Biol 3 (1999) 77-83
157. Merritt A.J., Allen T.D., Potten C.S., and Hickman J.A. Apoptosis in small intestinal epithelial from p53-null mice: evidence for a delayed, p53-independent G2/M-associated cell death after gamma-irradiation. Oncogene 14 (1997) 2759-2766
158. Zong W.X., Ditsworth D., Bauer D.E., Wang Z.Q., and Thompson C.B. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Gene Dev 18 (2004) 1272-1282
159. Jahr S., Hentze H., Englisch S., et al. DNA fragments in the blood plasma of cancer patients: quantitation and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61 (2001) 1659-1665
160. Linder S., Havelka A.M., Ueno T., and Shoshan M.C. Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker. Cancer Lett 214 (2004) 1-9
161. Kramer G., Erdal H., Mertens H.J., et al. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 64 (2004) 1751-1756
162. Olofsson M.H., Ueno T., Pan Y., et al. Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin Cancer Res 13 (2007) 3198-3206
163. Marini P., Denzinger S., Schiller D., et al. Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene 25 (2006) 5145-5154
164. Oltersdorf T., Elmore S.W., Shoemaker A.R., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435 (2005) 677-681